CryoCath Appoints New Chief Financial Officer

    Toronto Stock Exchange Symbol: CYT

    MONTREAL, Feb. 26 /CNW/ - CryoCath(R) Technologies Inc., the global
leader in cryotherapy products to treat cardiac arrhythmias, today announced
that Chief Financial Officer, L. Derek Lindsay, will be leaving the Company on
April 4, 2008. Effective April 7, 2008, Ginette Gagné will take over the role
of Chief Financial Officer at CryoCath. Mr. Lindsay has agreed to stay on in
the role of Chief Financial Officer to ensure a smooth transition.
    "Since joining CryoCath, Derek has been actively involved in significant
change and we thank him for his contributions to the Company's development and
wish him well for the future," said Jan Keltjens, President and Chief
Executive Officer of CryoCath. "I am very pleased to announce the appointment
of Ginette Gagné to the position of Chief Financial Officer at CryoCath. Her
extensive experience building and running world-class financial organizations,
combined with her hands-on experience in the global medical device business,
will support CryoCath in achieving our ambitious growth strategy."
    Over the past 19 years, Ginette has developed an impressive career track
record through leadership positions in various corporations with progressive
senior roles and responsibilities. She joins CryoCath from Boston Scientific
Corporation, where she most recently served as Vice President Finance of
Europe. In this capacity, she was responsible for managing a team of more than
150 people in 30 countries and played a key role in transitioning their
business from a highly centralized model to a country focused model. Before
this assignment she was the Vice President, Finance of Boston Scientific Inter
Continental. Prior to her eight years with Boston Scientific, Ginette held
financial leadership roles at Fisher Scientific International, Fisher France
OSI S.A. and Fisher Scientific Canada. She began her career with Northern
Telecom Ltd.

    About CryoCath

    CryoCath - - is a medical technology company that leads
the world in cryotherapy products to treat cardiac arrhythmias. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
cardiac arrhythmias.

    This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward looking statements, see CryoCath's annual
report available at under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.

    %SEDAR: 00015053EF

For further information:

For further information: visit our website at, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890